Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell Carcinoma
Public ClinicalTrials.gov record NCT06947928. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of IFx-Hu2.0 as an Adjunctive Therapy to Pembrolizumab in Checkpoint-Inhibitor Naïve Participants With Advanced or Metastatic Merkel Cell Carcinoma
Study identification
- NCT ID
- NCT06947928
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Lead sponsor
- TuHURA Biosciences, Inc.
- Industry
- Enrollment
- 118 participants
Conditions and interventions
Conditions
Interventions
- IFx-Hu2.0 Drug
- Pembrolizumab Drug
- Placebo Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Dec 10, 2025
- Primary completion
- Mar 30, 2027
- Completion
- Dec 29, 2032
- Last update posted
- Apr 16, 2026
2025 – 2032
United States locations
- U.S. sites
- 18
- U.S. states
- 12
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| USC Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| University of California San Francisco - Helen Diller Family Comprehensive Cancer Center | San Francisco | California | 94143 | Recruiting |
| Stanford Health Care - Skin Cancer Program | Stanford | California | 94304 | Recruiting |
| University of Colorado Hospital - Anschutz Cancer Pavilion | Aurora | Colorado | 80045 | Recruiting |
| Mayo Clinic Comprehensive Cancer Center | Jacksonville | Florida | 32224 | Recruiting |
| Sylvester Comprehensive Cancer Center | Miami | Florida | 33136 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Dana-Farber Cancer Institute | Boston | Massachusetts | 02215 | Recruiting |
| Mayo Clinic Comprehensive Cancer Center | Rochester | Minnesota | 55905 | Recruiting |
| Hackensack University Medical Center | Hackensack | New Jersey | 07601 | Recruiting |
| Atlantic Health System | Morristown | New Jersey | 07960 | Recruiting |
| East Carolina University | Greenville | North Carolina | 27834 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston | Texas | 77384 | Recruiting |
| Inova Schar Cancer | Fairfax | Virginia | 22031 | Recruiting |
| Virginia Commonwealth University | Richmond | Virginia | 23298 | Recruiting |
| Fred Hutchinson Cancer Research Center | Seattle | Washington | 98109 | Recruiting |
| West Virginia University | Morgantown | West Virginia | 26506 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06947928, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 16, 2026 · Synced May 20, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06947928 live on ClinicalTrials.gov.